Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPossibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
Pharmacology & Therapeutics, 06/24/09
Lordkipanidze M et al. - This review article describes the thrombotic risks associated with discontinuing antiplatelet therapy and the bleeding risks associated with continuing these drugs. By integrating the current understanding of the pharmacology of antiplatelet agents and the kinetics of platelet function recovery, this article unveils the possibility of a pharmacological rebound phenomenon which could lead to adverse ischemic events, and supports the warning against premature discontinuation of antiplatelet drugs issued in current guidelines.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Low levels of steroid-metabolizing hepatic enzyme activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose
Journal of Orthopaedic Science, 12/18/09
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 12/17/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
Current Medical Research and Opinion, 12/17/09
Evaluation of Anti-HBs Serum Levels and Pharmacokinetic Profile After Intravenous Administration of Niuliva, a New Hepatitis B Immunoglobulin, Following Liver Transplantation
Transplantation Proceedings, 12/17/09
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Leukemia and Lymphoma, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor